Bone Mineral Density in Type 2 Diabetes Patients with Charcot Arthropathy.


Journal

Current diabetes reviews
ISSN: 1875-6417
Titre abrégé: Curr Diabetes Rev
Pays: United Arab Emirates
ID NLM: 101253260

Informations de publication

Date de publication:
2019
Historique:
received: 10 11 2017
revised: 11 06 2018
accepted: 04 07 2018
pubmed: 12 7 2018
medline: 8 2 2020
entrez: 12 7 2018
Statut: ppublish

Résumé

Charcot arthropathy is one of the disabling diabetes complications. There are enigmatic areas concerning its underlying pathophysiology and risk predictors. Osteoporosis and local osteopenia have been postulated to have a role in Charcot arthropathy development, but it is still controversial. The study aims to compare bone mineral density among type 2 diabetics with and without Charcot arthropathy. Two groups with type 2 diabetes participated in this study; Group I [30] patients with Charcot arthropathy while Group II [30] patients without charcot arthropathy. All patients underwent full clinical examination and complete history taking with special emphasis on foot problems. Laboratory investigations were done that included fasting blood sugar, postprandial blood sugar, glycosylated hemoglobin, serum calcium, serum phosphorus, and alkaline phosphatase. All patients underwent MRI for both feet and dual energy X-ray absorptiometry scan of the lumbar spine and femur. The demographic data, clinical data, the presence or absence of comorbidities and bone mineral density were compared for both groups. Bone mineral density was significantly lower in Group I than Group II with median lumber T score (-0.15, 1.99 p <0.001), median Femur T score (0.050, 2.400, p <0.001). Group I showed higher propensity for hypertension, neuropathy, micro-albuminuria with peripheral arterial disease (23.33 %) compared to Group II (p <0.001). Multiple logistic regression analysis revealed that female gender and low femur bone mineral density can be risk predictors of the condition. Bone mineral density is lower in patients with Charcot arthropathy with female gender and Femur T score as risk predictors. Peripheral arterial disease shows greater incidence in Charcot patients than was previously reported.

Sections du résumé

INTRODUCTION BACKGROUND
Charcot arthropathy is one of the disabling diabetes complications. There are enigmatic areas concerning its underlying pathophysiology and risk predictors. Osteoporosis and local osteopenia have been postulated to have a role in Charcot arthropathy development, but it is still controversial.
BACKGROUND BACKGROUND
The study aims to compare bone mineral density among type 2 diabetics with and without Charcot arthropathy.
METHODS METHODS
Two groups with type 2 diabetes participated in this study; Group I [30] patients with Charcot arthropathy while Group II [30] patients without charcot arthropathy. All patients underwent full clinical examination and complete history taking with special emphasis on foot problems. Laboratory investigations were done that included fasting blood sugar, postprandial blood sugar, glycosylated hemoglobin, serum calcium, serum phosphorus, and alkaline phosphatase. All patients underwent MRI for both feet and dual energy X-ray absorptiometry scan of the lumbar spine and femur. The demographic data, clinical data, the presence or absence of comorbidities and bone mineral density were compared for both groups.
RESULT RESULTS
Bone mineral density was significantly lower in Group I than Group II with median lumber T score (-0.15, 1.99 p <0.001), median Femur T score (0.050, 2.400, p <0.001). Group I showed higher propensity for hypertension, neuropathy, micro-albuminuria with peripheral arterial disease (23.33 %) compared to Group II (p <0.001). Multiple logistic regression analysis revealed that female gender and low femur bone mineral density can be risk predictors of the condition.
CONCLUSION CONCLUSIONS
Bone mineral density is lower in patients with Charcot arthropathy with female gender and Femur T score as risk predictors. Peripheral arterial disease shows greater incidence in Charcot patients than was previously reported.

Identifiants

pubmed: 29992889
pii: CDR-EPUB-91628
doi: 10.2174/1573399814666180711115845
doi:

Substances chimiques

Glycated Hemoglobin A 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

395-401

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Hussein A El Oraby (HA)

Department of Endocrinology and Metabolism, Faculty of Medicine, Ain Shams University Hospitals, Cairo, Egypt.

Mona M Abdelsalam (MM)

Department of Endocrinology and Metabolism, Faculty of Medicine, Ain Shams University Hospitals, Cairo, Egypt.

Yara M Eid (YM)

Department of Endocrinology and Metabolism, Faculty of Medicine, Ain Shams University Hospitals, Cairo, Egypt.

Rana El Hilaly (R)

Department of Physical Medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Ain Shams University Hospitals, Cairo, Egypt.

Heba A Marzouk (HA)

Department of Endocrinology and Metabolism, Faculty of Medicine, Ain Shams University Hospitals, Cairo, Egypt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH